التفاصيل البيبلوغرافية
| العنوان: |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. |
| المؤلفون: |
Berenato, Rosa, Morano, Federica, Pietrantonio, Filippo, Cotsoglou, Christian, Caporale, Marta, Infante, Gabriele, Pellegrinelli, alessandro, alessi, alessandra, Battiston, Carlo, Coppa, Jorgelina, Padovano, Barbara, Mennitto, alessia, Niger, Monica, Fucà, Giovanni, Lazzati, Silvia, Greco, Giorgio, Delconte, Gabriele, de Braud, Filippo, Mazzaferro, Vincenzo, Di Bartolomeo, Maria |
| المصدر: |
Oncology; Oct2017, Vol. 93 Issue 5, p279-286, 8p |
| مصطلحات موضوعية: |
ANTIMETABOLITES, ANTINEOPLASTIC agents, CLINICAL trials, DEOXY sugars, PREOPERATIVE care, RADIOPHARMACEUTICALS, STOMACH tumors, TIME, POSITRON emission tomography, OXALIPLATIN, IRINOTECAN |
| مستخلص: |
Objectives: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. Methods: Patients affected by T3-T4/N0-N+/M0 GC/GEJ cancer were treated with the COI regimen for 4 cycles followed by restaging and gastroresection with D2 lymphadenectomy. Four postoperative cycles were scheduled. The primary endpoint was pathological response rate according to Becker et al. [Cancer 2003; 98: 1521-1530]. The potential role of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as a predictive biomarker of pathological tumor response was assessed in a subgroup of 19 evaluable patients. Results: Between January 2011 and October 2015, a total of 40 patients were enrolled. After the preoperative phase, 36 out of 40 patients (90%) were considered eligible for surgery: 12 patients (30%) achieved a pathological response. The most frequent grade 3/4 adverse events were diarrhea (27%), nausea (25%), and fatigue (17%). Grade 3 neutropenia occurred in 7.5% of patients. A lower standard uptake value at baseline FDG-PET/CT was associated with pathological response. Conclusion: COI combination is active with a manageable toxicity profile in patients with resectable GC or GEJ cancer. FDG-PET/CT imaging as a surrogate biomarker of pathological response in this setting appears fascinating but should be further investigated. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
